MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
Precigen Market Cap 2011-2026 | PGEN
As of May 20, 2026 Precigen has a market cap of $ 1.34 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Precigen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 970 M | 830 M | 352 M | 232 M | 510 M | 1.42 B | 748 M | 997 M | 1.59 B | 2.48 B | 3.24 B | 2.85 B | 1.35 B | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.24 B | 232 M | 1.35 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
50.7 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
8.91 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
29.1 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
115 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
1.62 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
740 M | - | 0.74 % | $ 768 M |  Israel |
 |
Galera Therapeutics
GRTX
|
7.65 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
1.44 B | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
561 M | $ 3.14 | 0.16 % | $ 653 M | USA |
 |
Eton Pharmaceuticals
ETON
|
559 M | $ 34.42 | 4.65 % | $ 926 M | USA |
|
Forte Biosciences
FBRX
|
335 M | $ 20.35 | 1.4 % | $ 263 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
52.7 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
10.6 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
217 M | $ 6.84 | 2.17 % | $ 187 M | Israel |
 |
Grifols, S.A.
GRFS
|
4.52 B | $ 8.21 | 4.72 % | $ 5.58 B |  Spain |
 |
Generation Bio Co.
GBIO
|
179 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
6.84 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
22 B | $ 90.48 | 3.06 % | $ 21.9 B | Germany |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.64 | 0.61 % | $ 436 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
198 M | $ 0.85 | 0.57 % | $ 142 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
109 K | - | -4.36 % | $ 27 M | USA |
 |
Compugen Ltd.
CGEN
|
196 M | $ 2.74 | 0.18 % | $ 256 M | Israel |
 |
Anika Therapeutics
ANIK
|
214 M | $ 15.15 | 2.23 % | $ 217 M | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
14.8 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
13.5 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 3.39 | 4.17 % | $ 5.58 M | Israel |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
226 M | $ 1.52 | 2.7 % | $ 178 M | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 20.45 | 4.9 % | $ 2.6 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |